Immunic Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals

New york , april 4, 2024 /prnewswire/ --  immunic, inc.  (nasdaq: imux), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that it will host a multiple sclerosis (ms) research and development (r&d) day and participate in the following investor conferences in april: april 9: immunic's ms r&d day . management of immunic, including daniel vitt, ph.d.

– patent will also cover a related method of production of the material – – fourth u.s. patent directed to use of vidofludimus calcium in multiple sclerosis – – multilayered intellectual property strategy provides protection into 2041 in the united states and into 2039 internationally, unless extended further – new york, march 20, 2024 /prnewswire/ -- immunic, inc.  (nasdaq: imux), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that it has received a notice of allowance from the united states patent and trademark office (uspto) for patent application 16/981,122, entitled, "calcium salt polymorphs as anti-inflammatory, immunomodulatory and anti-proliferative agents," covering the composition-of-matter of a specific polymorph of vidofludimus calcium (imu-838) and a related method of production of the material...

New york , march 7, 2024 /prnewswire/ --  immunic, inc.  (nasdaq: imux), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following investor and scientific conferences in march: march 11-13: leerink partners global biopharma conference . daniel vitt, ph.d.

New york , feb. 29, 2024 /prnewswire/ --  immunic, inc.  (nasdaq: imux), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced the presentation of data from the company's phase 2 calliper and calvid-1 clinical trials of lead asset, nuclear receptor related 1 (nurr1) activator, vidofludimus calcium (imu-838), in two poster presentations at the americas committee for treatment and research in multiple sclerosis (actrims) forum 2024, taking place from february 29 to march 2, in west palm beach, fl. "having two poster presentations on our lead asset, vidofludimus calcium, at the prestigious actrims forum is a testament to the strength of the data we have generated," stated daniel vitt, ph...

– significantly strengthened balance sheet in january 2024 with execution of three-tranche private placement of up to $240 million, extending cash runway into the third quarter of 2025 based on initial $80 million tranche – – evidence for neuroprotective activity of vidofludimus calcium from phase 2 calliper interim analysis, consistent across the entire progressive multiple sclerosis population and all subtypes; top-line calliper data expected in april 2025 – – phase 3 ensure program in relapsing multiple sclerosis ongoing – – expanded vidofludimus calcium patent portfolio  with additional new patents granted; exclusivity protection expected into 2041 in the united states, unless extended further – – webcast to be held today, february 22, 2024, at 8:00 am et – new york , feb...

Immunic Inc (NASDAQ:IMUX) has received a Notice of Allowance for a composition-of-matter patent covering a specific polymorph of vidofludimus calcium, which is being advanced as a treatment for chronic inflammatory and autoimmune diseases, particularly multiple sclerosis. The patent, titled "Calcium salt polymorphs as anti-inflammatory, immunomodulatory and anti-proliferative agents", solidifies the company's intellectual property protection around its lead, late-stage asset.

Immunic Inc (NASDAQ:IMUX) announced that it will present data from its Phase 2 CALLIPER and CALVID-1 clinical trials of its lead asset vidofludimus calcium (IMU-838) at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2024. "Having two poster presentations on our lead asset, vidofludimus calcium, at the prestigious ACTRIMS Forum is a testament to the strength of the data we have generated," Immunic CEO Dr. Daniel Vitt said in a statement.

Biotechnology company Immunic Inc (NASDAQ:IMUX) disclosed its financial results for the fourth quarter and year ended December 31, 2023, alongside significant clinical advancements, marking a pivotal year for the firm. Immunic CEO Daniel Vitt lauded the company's strides in 2023, citing the successful completion of a three-tranche private placement worth up to $240 million.

The journey toward effective therapies for patients with multiple sclerosis (MS) is marked by persistent challenges. Despite advancements in addressing relapses, the specter of disability progression looms large, leaving a significant unmet need in patient care.

– Webcast to be Held at 8:00 am ET on February 22, 2024 – NEW YORK , Feb. 15, 2024 /PRNewswire/ --  Immunic, Inc.  (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that the company will release its financial results for the fourth quarter and year ended December 31, 2023, including a corporate update, on Thursday, February 22, 2024, before the opening of the U.S. financial markets. A webcast will follow at 8:00 am ET.

Immunic Inc (NASDAQ:IMUX) Chief Scientific Officer Hella Kohlhof sheds light on her crucial role and the groundbreaking strides being made in the scientific world ahead of the International Day of Women and Girls in Science on 11 February. As CSO, Kohlhof is pivotal in crafting the scientific strategy for Immunic's projects, focusing on understanding molecular actions, ensuring safety in preclinical regulatory work, and developing biomarkers for early activity indications.

Immunic Inc (NASDAQ:IMUX) shares took off after the biotechnology firm announced it would be raising up to $240 million in a private placement. Immunic stock was up 11.2% at US$1.58 before Friday's opening bell.

Immunic, Inc. said the US Patent and Trademark Office has given it a notice of allowance for patent application 17/992,162 entitled entitled 'Compounds and Dosage Regimen for Use in the Prevention or Treatment of Chronic Inflammatory and/or Autoimmune Diseases'. The patent covers dosing regimens associated with the company's lead asset, vidofludimus calcium and other salt forms as well as free acid forms for the treatment of multiple sclerosis, providing protection into 2038.

Immunic, Inc. (NASDAQ:IMUX ) Q3 2023 Earnings Conference Call November 14, 2023 8:00 AM ET Company Participants Jessica Breu - Head of IR & Communications Dr. Daniel Vitt - CEO and President Glenn Whaley - CFO Conference Call Participants Caroline Pocher - Wedbush PacGrow Liam Hiester - Piper Sandler Matt Kaplan - Ladenberg Thalmann Tom Smith - Leerink Partners William Wood - B. Riley Jessica Breu Good morning, and welcome to Immunic's Third Quarter 2023 Earnings Call.

Immunic Inc (NASDAQ:IMUX) – a biotechnology company developing a pipeline of orally administered small molecule therapies for chronic inflammatory and autoimmune diseases - during the three months ending in September advanced its lead drug asset, a nuclear receptor-related 1 (Nurr1) activator vidofludimus calcium IMU-838. Immunic exited the third quarter with cash, cash equivalents and investments of $59.7 million which it said it expects will fund its operations into September of 2024.